Genomic Health Gets KO'd By Next-Gen Long-Term Breast Cancer Assays
The new-generation of tests from Myriad and NanoString have outperformed Genomic Health's Oncotype Dx in predicting which breast cancer patients are at low-risk for a recurrence in five to ten years, and therefore do not need to be on extended endocrine therapy.
You may also be interested in...
Device Debuts: Tryton, Myriad Genetics, Integra Lifesciences, Acelity, And Toyota
This edition of device debuts highlights a wide variety of innovative devices introduced into commercial markets since the beginning of March, including a new stent for side-branch coronary interventions, an assay that identifies which breast-cancer patients do not need chemotherapy, a full ankle prosthesis, improvements to a negative-pressure wound therapy system, and a robotic system that helps paralyzed people learn to walk again.
Minute Insight: Bayer Launches Precision Health Unit To Focus On Digital Consumer Health
The pharma giant said the new division will help people take control of their own health care with digital products.
Medtronic Creates Chief Technology And Innovation Officer Role
Ken Washington, the former general manager of consumer robotics, will help the company “accelerate innovation-driven growth.”